| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $14.7M | +2270.6% |
| Cost of Revenue | $0 | — |
| R&D Expense | $190.1M | -18.2% |
| SG&A Expense | $168.8M | +30.2% |
| Operating Income | -$344.2M | +5.0% |
| Interest Expense | $114.7M | -11.2% |
| Pre-tax Income | -$413.6M | +29.2% |
| Income Tax | $0 | +100.0% |
| Net Income | -$413.6M |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $143.4M | -46.0% |
| Short-term Investments | $6.4M | +532.4% |
| Accounts Receivable | $2.4M | — |
| Inventory | $8.3M | — |
| Current Assets | $184.6M | -37.2% |
| Total Assets | $382.9M | -24.1% |
| Current Liabilities | $54.9M | -5.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$391.2M | -6.7% |
| Capital Expenditures | $6.9M | -77.5% |
| Investing Cash Flow | -$12.2M | +59.8% |
| Financing Cash Flow | $281.6M | -49.6% |
| Free Cash Flow | -$398.1M | -0.2% |
| +29.1% |
| EPS (Basic) | -$0.59 | +48.7% |
| EPS (Diluted) | -$0.62 | +46.1% |
| Total Liabilities |
| $871.1M |
| -20.1% |
| Stockholders' Equity | -$489.1M | +16.7% |